Plain English summary T his review updates a previous review of methods for assessing the impact of programmes such as the National Institute for Health Research Health Technology Assessment (HTA) programme. This review confirmed the earlier finding that the Payback Framework was, and remains, the main method used internationally. This work also reviewed the wider literature to develop a taxonomy of different underlying approaches to measuring impact. On the basis that it is robust, flexible and remains the most widely used approach internationally, we found that the Payback Framework remained an appropriate approach for the HTA programme to use.
Three extensions to the Payback Framework were examined in more detail, the first in relation to expressing impact in terms of its monetary value. Studies using the approach generally show big returns from investment in health research. A first attempt to apply this to the HTA programme found similar results.
As the results of randomised trials mainly impact on clinical guidelines through systematic reviews, we checked how often trials funded by the HTA programme were included in systematic reviews undertaken after these trials were published. We found that around one-quarter of such trials were included in later reviews by the Cochrane Collaboration. We recommended that the programme consider what its impact might be on systematic reviews and clinical guidelines for each trial it publishes.
The third extension considered whether or not, and to what extent, trials funded by the HTA programme successfully stopped the spread of new technologies that had failed to show benefit; we found that this was rare. Around one-quarter of trials funded by the programme could be considered 'first in class', but many were variants of existing technologies rather than entirely new. Areas for further research include exploring the benefits to the HTA programme of, considering the impact on systematic reviews and clinical guidelines from each trial it publishes, and second, monitoring the extent to which the trials it funds are 'first in class'.
